(vianews) - shares of erytech pharma (cac 40: eryp.pa) jumped by a staggering 12.52% to €0.89 at 13:59 est on thursday, after two sequential sessions in a row of gains. cac 40 is falling 0.51% to €7,094.54, after three successive sessions in a row of gains. this seems, up until now, a somewhat negative trend trading session today.
erytech pharma's last close was €0.80, 64.82% under its 52-week high of €2.26.
about erytech pharma
erytech pharma s.a., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in france and the united states. its lead product candidate is eryaspase, which is in phase 3 clinical development for the treatment of second-line pancreatic cancer, and in phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. the company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. the company was incorporated in 2004 and is headquartered in lyon, france.
earnings per share
as for profitability, erytech pharma has a trailing twelve months eps of €-1.14.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, erytech pharma's stock is considered to be oversold (<=20).
revenue growth
year-on-year quarterly revenue growth declined by 58.5%, now sitting on 2.2m for the twelve trailing months.
volume
today's last reported volume for erytech pharma is 893342 which is 34.07% above its average volume of 666276.
volatility
erytech pharma's last week, last month's, and last quarter's current intraday variation average was a positive 4.07%, a negative 0.65%, and a positive 6.09%.
erytech pharma's highest amplitude of average volatility was 4.82% (last week), 5.02% (last month), and 6.09% (last quarter).
more news about erytech pharma (eryp.pa).